Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 20/20 | 0.78 |
| ▸ | HTR2A | P28223 | 20/20 | 0.78 |
| ▸ | DRD3 | P35462 | 20/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1394640 | 1.00 | DRD2 (0.78) | DRD2HTR2ADRD3 | |
| SCHEMBL321924 | 0.93 | DRD2 (0.78) | DRD2HTR2ADRD3 | |
| SCHEMBL1394484 | 0.93 | DRD2 (0.78) | DRD2HTR2ADRD3 | |
| SCHEMBL1394839 | 0.92 | DRD2 (0.78) | DRD2HTR2ADRD3 | |
| SCHEMBL321853 | 0.92 | DRD2 (0.78) | DRD2HTR2ADRD3 | |
| SCHEMBL1393914 | 0.92 | DRD2 (0.77) | DRD2HTR2ADRD3 | |
| SCHEMBL322539 | 0.92 | DRD2 (0.77) | DRD2HTR2ADRD3 | |
| SCHEMBL323175 | 0.91 | DRD2 (0.78) | DRD2HTR2ADRD3 | |
| SCHEMBL1394064 | 0.91 | DRD2 (0.78) | DRD2HTR2ADRD3 | |
| SCHEMBL322611 | 0.90 | DRD2 (0.78) | DRD2HTR2ADRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2590984-B1 | ANELLATED PYRIDINE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2015-01-28 | — | — | EP | claimed |
| US-8470828-B2 | Anellated pyridine compounds | HOFFMANN-LA ROCHE INC. (US) | 2013-06-25 | — | — | US | claimed |
| US-20120010201-A1 | NOVEL ANELLATED PYRIDINE COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2012-01-12 | — | — | US | claimed |
| EP-2590984-B1 | ANELLATED PYRIDINE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2015-01-28 | — | — | EP | disclosed |
| US-8470828-B2 | Anellated pyridine compounds | HOFFMANN-LA ROCHE INC. (US) | 2013-06-25 | — | — | US | disclosed |
| EP-2590984-A1 | ANELLATED PYRIDINE COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-05-15 | — | — | EP | disclosed |
| WO-2012004206-A1 | ANELLATED PYRIDINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-12 | — | — | WO | disclosed |
| US-20120010201-A1 | NOVEL ANELLATED PYRIDINE COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010201-A1 | NOVEL ANELLATED PYRIDINE COMPOUNDS | ADORA3, ADORA2A, HTR3A | DRD2 57/4885HTR2A 4/4885DRD3 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.